This seminar series focuses on key challenges of the prevention, treatment and patient management approaches associated with viral hepatitis, advancing cirrhosis, liver cancer and fatty liver disease.

- Updated content based on the latest medical guidelines and clinical trial results
- Strong patient-focused educational sessions employing evidence-based studies from the latest AASLD, EASL and DDW programs
- Local experts at each program provide an interdisciplinary, team approach to patient care
- A highly interactive format that stresses improved patient outcomes
- BONUS SESSION on SARS-CoV-2 and Liver Disease
- Participants can receive up to 10.0 AMA PRA Category 1 Credits™ or up to 12 nursing education credits

WHO SHOULD ATTEND?
This program was developed for Gastroenterologists, Internists, Hepatologists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists.

THE BENEFITS OF PARTICIPATION
- Acquire countless practice pearls from the nation’s top liver disease specialists
- Gain new insight on the cutting edge approaches to optimize clinical outcomes for your patients
- Participate with local colleagues to solve real-world clinical cases
- Utilize the clinical resources and referral opportunities found in your community

2022 An evidence-based, hybrid seminar series focused on Viral Hepatitis, ESLD, HCC, PBC and NASH

NEW FOR THE 2022 SEMINAR SERIES
- Updated COVID-19 Precautions for the health and safety of our participants
- How Alcohol and Alcohol Abuse is Increasing Liver Disease
- Treating Chronic Liver Disease in Special Populations
- SARS-CoV2 and the Long-term Effect on Liver Health
- New content, lectures and case studies reflecting the current advances in diagnosis, treatment and patient care
- A hybrid delivery platform that utilizes live, P2P-presentations and/or web-based lectures to maximize learning and time efficiency

FRESH THINKING & THE NEWEST ADVANCES START HERE

For more information or to register for either the live or enduring material, please go to: https://bit.ly/hepandCLD22 for more details.
Available in both a live seminar or a web-based enduring material, the program features timely lectures, case analysis, clinical trial outcomes and progress reports on promising prevention approaches and emerging therapies.

The seminar will concentrate on key diseases of the liver and address the latest in interactive learning, audience participation, and collaborative discussion.

Available in both a live seminar or a web-based enduring material, the program will increase the number of clinicians educated in preventing, diagnosing, and treating, and/or referring liver-disease patients for more advanced care. The goal of this CME activity is to forecast future cases and improve the outcomes of those already affected.

WHY SHOULD YOU PARTICIPATE?

• Treat liver disease in special populations
• Alcoholic liver disease and Alcoholic Hepatitis
• Elimination approaches to Hepatitis B
• SARS-CoV-2 and Liver Disease

Fresh clinical cases to test your knowledge of both clinical theory and the latest in clinical practice will be presented. The interactive style of this activity makes it perfect for continuing education in both special and general medicine.

PROGRAM TOPICS

- Delta Hepatitis and Hepatitis E Update
- Hepatitis B: Epidemiology, Natural History and Testing
- Hepatitis A: Diagnosis and Treatment
- Hepatocellular Carcinoma: Screening and disease management approaches
- Hepatocellular Carcinoma: New Systemic Treatment Options
- SARS-CoV-2 and Liver Disease
- Promising Therapies for Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis (PBC)
- Alcoholic Liver Disease
- Epidemiology, Demographics and Diagnosis of Fatty Liver Disease
- NASH Treatments in Practice and in Development
- Overcoming the Barriers to Liver Health in Special Populations
- Closing Comments and Post Test

After attending this activity, participants should be able to:

- Review the history, epidemiology, demographics, natural history, immunology, and pathophysiology that led to increased incidence of viral hepatitis.
- Explain the factors that have led to a resurgence of Hepatitis A and the diagnosis and treatment guidelines for Delta Hepatitis and Hepatitis E.
- Review the current therapies for PBC and clinical approaches for PSC.
- Incorporate new and emerging treatment regimens for PBC from the latest EASL and ASLSL presented papers.
- Summarize the changes of chronic liver disease and hepatic encephalopathy and promising treatments.
- Explore the causes and impact of alcohol on liver wellbeing and progressive liver disease.
- Perform the appropriate diagnostic tests required to early diagnosis of hepatocellular carcinoma.
- Integrate new treatment options for HCC as well as approaches to reduce tumor size and number.
- Discuss the barriers to liver disease elimination and the unique challenges and special populations.
- Employ the progression pathways of Fatty Liver Disease to NASH to Liver Cancer to improve patient management.
- Heal the health implementing of HCV patients, liver cancer and other progressive liver diseases.
- Explore the causes and impact of alcohol on liver wellbeing and progressive liver disease.


To call SC Liver Research Consortium at (252) 432-4022

Early Registration ends Wednesday prior to the program date.

CANCELLATION POLICY: Requests for cancellations must be submitted to emailed to registration@SCLRC.org no later than 7 days prior to the program. Such requests will receive a full refund less a $200 processing fee.